Antigenic Divergence between Bordetella pertussis Clinical Isolates from Moscow, Russia, and Vaccine Strains
- 1 March 2007
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (3) , 234-238
- https://doi.org/10.1128/cvi.00294-06
Abstract
We analyzed temporal changes in the frequencies of the ptxA , prn , fim2 , and fim3 alleles in Bordetella pertussis strains isolated from pertussis patients in Moscow, Russia, from 1948 to 2004. The three strains used for the whole-cell vaccine harbored the alleles ptxA2 , ptxA4 , prn1 , fim2-1 , and fim3A . Vaccine-type alleles of ptxA ( ptxA2 and ptxA4 ) were characteristic for all prevaccination strains and for 96% of the strains isolated in the 1960s and 1970s. At the beginning of the 1970s, ptxA2 and ptxA4 were replaced by the ptxA1 allele. In the 1980s and to the present, strains with ptxA1 were predominant in the B. pertussis population. All prevaccination strains harbored the prn1 allele, which corresponds to the vaccine-type allele. In subsequent years, the proportion of strains with the prn1 allele decreased and the proportion of prn3 and prn2 strains increased. From 2002 to 2004 strains with prn2 or prn3 were predominant in the B. pertussis population. The vaccine-type alleles fim2-1 and fim3A were found in all prevaccination strains and in 92% of the strains isolated from 1960 to 1989. The fim2-2 and fim3B alleles were first observed at the beginning of the 1980s. In subsequent years, these strains became predominant. Together with waning immunity, the antigenic divergence between vaccine strains and clinical isolates observed in the Moscow area may explain the persistence of pertussis, despite the high rates of vaccine coverage. The results demonstrate that the selection of B. pertussis strains for vaccine manufacturing must be based on a thorough study of the B. pertussis population.Keywords
This publication has 30 references indexed in Scilit:
- Genetic and antigenic analysis ofBordetella pertussisisolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccineCanadian Journal of Microbiology, 2005
- Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene VariantsJournal of Clinical Microbiology, 2004
- Comparison of the Bordetella pertussis and Bordetella parapertussis Isolates Circulating in Saint Petersburg between 1998 and 2000 with Russian Vaccine StrainsJournal of Clinical Microbiology, 2003
- Multilocus Sequence Typing of Bordetella pertussis Based on Surface Protein GenesJournal of Clinical Microbiology, 2002
- Polymorphism of Bordetella pertussis Isolates Circulating for the Last 10 Years in France, Where a Single Effective Whole-Cell Vaccine Has Been Used for More than 30 YearsJournal of Clinical Microbiology, 2001
- Genotypic Variation in the Bordetella pertussis Virulence Factors Pertactin and Pertussis Toxin in Historical and Recent Clinical Isolates in the United KingdomInfection and Immunity, 2001
- Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance DataEmerging Infectious Diseases, 2000
- Temporal Trends in the Population Structure ofBordetella pertussisduring 1949–1996 in a Highly Vaccinated PopulationThe Journal of Infectious Diseases, 1999
- Return of epidemic pertussis in the United StatesThe Pediatric Infectious Disease Journal, 1994
- An agglutinative reaction for hemophilus pertussis: II. Its relation to clinical immunityThe Journal of Pediatrics, 1943